Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bloodworks

Neither a doctor nor a teaching hospital

Research payments

$793,404

92 payments

Through program year 2025, Bloodworks is reported as receiving $793,404 in research payments, across 92 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $122,859 2
2024 Research $122,859 2
2023 Research $16,303 1
2022 Research $175,859 7
2021 Research $173,651 25
2020 Research $145,631 37
2019 Research $36,243 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Immucor, Inc. $245,717 4 payments
  2. Becton, Dickinson and Company $160,921 4 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $139,414 36 payments
  4. Pfizer Inc. $77,664 18 payments
  5. Bioverativ Therapeutics Inc. $65,581 4 payments
  6. Roche Diagnostics Operations, Inc. $57,205 1 payment
  7. Spark Therapeutics, Inc. $28,908 13 payments
  8. Shire North American Group Inc $17,994 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. Evaluation of Extended Phenotype Assays $161,482 2 payments
  2. Lyricleumc $160,921 4 payments
  3. A Phase 1/2 Open-Label, Single Ascending Dose Trial of A Self-Complementing Optimized Adeno-Associated Virus Serotype 8 Factor IX Gene Therapy (Askbio009) in Adults With Hemophilia B $95,347 9 payments
  4. Evaluation of Automated Capture-P Assay $84,236 2 payments
  5. A Phase 12 Openlabel Adaptive Doseranging Study to Assess the Safety and Tolerability of Sb525 Pf07055480 Recombinant Aav26 Human Factor 8 Gene Therapy in Adult Subjects With Severe Hemophilia A $67,243 7 payments
  6. Cimrd005615 $57,205 1 payment
  7. Global Epidemiologic Study of Preexisting Immunity to Aav in Adults With Severe Hemophilia $46,909 20 payments
  8. A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients >=12 Years of Age With Severe Hemophilia A $33,525 3 payments
  9. A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients >= 12 Years of Age With Severe Hemophilia A $32,057 1 payment
  10. A Multi-Center, Observational Study in Males With Hemophilia A $28,908 13 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $84,236 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record